HONG KONG – Shanghai-based Fosun Kite Biotechnology Co. Ltd. was granted approval from China's National Medical Products Administration (NMPA) to advance its gene therapy candidate, FKC-876, to clinical trials. Read More
HONG KONG – Amid renewed interest in CD47 as an immuno-oncology target, Innovent Biologics Inc., of Suzhou, China, has received IND approval in China to start clinical trials of its monoclonal antibody (MAb), IBI-188. To further get ahead in the anti-CD47 race, Innovent will conduct clinical trials on IBI-188 at home and abroad simultaneously. Read More
Cholangiocarcinoma, also known as bile duct cancer, is one of those rare diseases that previously gained little attention from the biopharma community. It has a small population and is challenging to treat. About 8,000 people in the U.S. are diagnosed each year, and most learn they have the disease at the late stages when the prognosis is poor. Read More
PERTH, Australia – Following its IPO on Australia's Securities Exchange last year, radiopharma company Telix Pharmaceuticals Ltd. has been building global partnerships to prepare for a commercial build-up of its theranostic radiopharmaceuticals. To add to its arsenal, Telix has exercised an option to acquire Atlab Pharma SAS for $10 million to de-risk its prostate cancer monoclonal antibody (MAb), TLX-591. Read More
KARACHI, Pakistan – Without any domestic production capacity and facing virtually chronic shortages of vaccines on the market, Pakistan is now partnering with China to build capacity and working to create a policy environment more conducive to facilitating production. Read More
PERTH, Australia – Cellmid Ltd.'s lead anti-midkine antibody, CAB-102, reduced kidney injury and preserved renal function in a preclinical model of focal segmental glomerulosclerosis (FSGS), according to studies performed at the Westmead Institute in New South Wales. Read More
Sun Pharmaceutical Industries Ltd., of Mumbai, India, and subsidiary Sun Pharma Advanced Research Co. Ltd. (SPARC), of Princeton, N.J., received FDA approval for Xelpros (latanoprost ophthalmic emulsion), triggering an undisclosed milestone payment to SPARC under the firms' 2015 deal. SPARC also is eligible for milestones and royalties on commercialization of Xelpros in the U.S. Read More
Travecta Therapeutics Pte Ltd., of Singapore, appointed Douglas C. Hicks chief business officer. He will serve on the executive leadership team and lead business development and corporate strategy for the company. Read More